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Hemispatial neglect following right-hemisphere stroke is a common and disabling disorder, for which there is currently no
effective pharmacological treatment. Dopamine agonists have been shown to play a role in selective attention and working
memory, two core cognitive components of neglect. Here, we investigated whether the dopamine agonist rotigotine would have
a beneficial effect on hemispatial neglect in stroke patients. A double-blind, randomized, placebo-controlled ABA design was
used, in which each patient was assessed for 20 testing sessions, in three phases: pretreatment (Phase A1), on transdermal
rotigotine for 7–11 days (Phase B) and post-treatment (Phase A2), with the exact duration of each phase randomized within
limits. Outcome measures included performance on cancellation (visual search), line bisection, visual working memory, selective
attention and sustained attention tasks, as well as measures of motor control. Sixteen right-hemisphere stroke patients were
recruited, all of whom completed the trial. Performance on the Mesulam shape cancellation task improved significantly while on
rotigotine, with the number of targets found on the left side increasing by 12.8% (P = 0.012) on treatment and spatial bias
reducing by 8.1% (P = 0.016). This improvement in visual search was associated with an enhancement in selective attention but
not on our measures of working memory or sustained attention. The positive effect of rotigotine on visual search was not
associated with the degree of preservation of prefrontal cortex and occurred even in patients with significant prefrontal involve-
ment. Rotigotine was not associated with any significant improvement in motor performance. This proof-of-concept study
suggests a beneficial role of dopaminergic modulation on visual search and selective attention in patients with hemispatial
neglect following stroke.
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Introduction
Hemispatial neglect is a common disorder, most pronounced and
long-lasting after right-hemisphere stroke, with up to two-thirds of
such patients affected in the acute phase (Stone et al., 1991;
Bowen et al., 1999). These individuals demonstrate a striking fail-
ure to acknowledge or respond to people or objects to their left
and are often oblivious of their existence. Enduring neglect has
repeatedly been recognized as a poor prognostic indicator for
functional independence following stroke (Denes et al., 1982;
Fullerton et al., 1988; Kalra et al., 1997; Jehkonen et al., 2000;
Cherney et al., 2001). However, despite its clinical impact, the
syndrome is underdiagnosed (Edwards et al., 2006; Menon-Nair
et al., 2006), and treatment options remain extremely limited.
Although several studies have shown promising effects of
non-drug interventions such as prismatic deviation or alerting
(Rossetti et al., 1998; Wilson et al., 2000; Barrett et al., 2006;
Luaute´ et al., 2006), there is no established drug therapy that has
been adopted for clinical use (Lincoln and Bowen, 2006; Bowen
et al., 2007).
Rather than being a unitary disorder, neglect is a syndrome
consisting of several component deficits (Heilman and
Valenstein, 1979; Mesulam, 1999; Husain and Rorden, 2003;
Hillis, 2006; Bartolomeo, 2007), with different patients suffering
different combinations of cognitive impairment (Buxbaum et al.,
2004). For example, difficulties in disengaging or directing spatial
attention, initiating or executing movements, sustaining attention
over time and representing space to the left have all been reported
in individuals with the syndrome (Posner et al., 1984; Gainotti
et al., 1991; Robertson et al., 1997a, 1998; Bartolomeo et al.,
1998; Mattingley et al., 1998; Bisiach and Luzzatti, 1978;
Bartolomeo and Chokron, 2002; Coulthard et al., 2006). A poten-
tially important component demonstrated in recent studies is a
deficit in remembering spatial locations over brief periods of
time or spatial working memory (Wojciulik et al., 2001; Pisella
et al., 2004; Malhotra et al., 2005; Mannan et al., 2005; Ferber
and Danckert, 2006; Parton et al., 2006), which can interact with
deficits in sustained attention to exacerbate neglect (Malhotra
et al., 2009).
Dopamine within prefrontal cortex has now been established to
play a crucial role in both attention and working memory.
Landmark studies in monkeys have shown that visuospatial work-
ing memory in monkeys is modulated by dopamine (Funahashi
and Kubota, 1994; Goldman-Rakic, 1996; Goldman-Rakic et al.,
2000), specifically via prefrontal dopamine D1 receptors (Williams
and Goldman-Rakic, 1995). Indeed, a selective D1 agonist can
enhance working memory in aged monkeys (Castner and
Goldman-Rakic, 2004) or reverse experimentally induced spatial
working memory deficits (Castner et al., 2000). In healthy
humans too, D1—but not D2—dopamine receptor agonists can
facilitate spatial working memory (Mu¨ller et al., 1998).
In addition to its pivotal role in working memory, new findings
suggest that frontal D1 receptor activity can have long-range,
modulatory effects on visual areas subserving attention. Thus,
local infusion of a D1 antagonist into monkey frontal cortex not
only modulated the firing of neurons in visual cortex but also
altered the animal’s ability to select visual targets (Noudoost and
Moore, 2011). Furthermore, dopaminergic neuronal networks
have a well-recognized role in alerting or allocating attention to
unexpected sensory cues based on the potential importance or
behavioural relevance of the stimulus (Bromberg-Martin et al.,
2010). These findings raise the possibility of modulating D1 recep-
tor activity to alter attention and/or working memory and thereby
ameliorate neglect in stroke patients.
There have previously been few attempts to test modulation of
dopaminergic activity as a therapeutic option in hemispatial neg-
lect, but the largest trial tested only four patients. Despite some
initial promising results from an open-label study in two patients
using bromocriptine, a predominantly D2 dopamine receptor
agonist (Fleet et al., 1987), a further small open-label trial and a
case report revealed worsening of neglect with the drug (Grujic
et al., 1998; Barrett et al., 1999). Apomorphine, which has both
D1 and D2 receptor activity, induced a transient improvement in
three of four neglect patients tested (Geminiani et al., 1998). In
keeping with this finding, an open-label study showed some im-
provement in standard neglect tests following treatment with
levodopa in three of four cases studied (Mukand et al., 2001).
Finally, a small-scale trial of amantadine in four neglect patients
did not demonstrate any beneficial effect of the drug (Buxbaum
et al., 2007).
We conducted a double-blind, randomized, placebo-controlled
trial of the dopamine agonist rotigotine in 16 patients with hemi-
spatial neglect and unilateral weakness following right-hemisphere
stroke. In contrast to the substances tested in previous studies, we
used rotigotine, which has high affinity for the D1 receptor com-
pared with many other licensed oral dopamine agonists (Jenner,
2005; Naidu and Chaudhuri, 2007). Our primary objective was to
evaluate whether the drug improves neglect and its cognitive
components, including selective and sustained attention, as well
as spatial working memory. A further aim was to assess the effects
of rotigotine on motor performance, because some previous stu-
dies have suggested that levodopa may have a positive effect on
motor deficits following stroke (Scheidtmann et al., 2001;
Scheidtmann, 2004; Floel et al., 2005). Since prefrontal cortex is
an important potential candidate area for the cognitive effects of
dopamine agonists, we sought to determine whether any benefi-
cial effects of rotigotine depend on the extent of preservation of
the right prefrontal cortex.
Patients were assessed with a battery of standardized neglect
tests, as well as with tests of working memory, selective and sus-
tained attention and motor function. We used a replicated ABA
double-blind, placebo-controlled N-of-1 randomized design, which
allowed us to evaluate the effectiveness of an intervention in small
sample sizes. Each patient’s performance was measured in three
phases, each consisting of several assessment sessions: before
treatment (Phase A1), while receiving transdermal rotigotine
(Phase B) and after discontinuation of the drug (Phase A2).
Crucially, the exact duration of each phase was randomized
across patients. Performance on rotigotine was compared with
the pre-treatment baseline and post-treatment follow-up phases.
The principles of randomized N-of-1 designs (Edgington and
Onghena, 2007), such as the one used here, were originally
described by Fisher (1935) for intervention studies, but were
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difficult to conduct on a large scale because they require substan-
tial computing power. As a result, few investigators used them.
However, modern-day computers make the mathematical
demands far less problematic and replicated randomized N-of-1
designs provide a powerful way to assess effects in highly focused
studies using a large number of assessments on small patient sam-
ples. Randomization or permutation tests are used for analysis of
these designs. Importantly, such tests are distribution-free. They
are based simply on rearrangements of raw scores. They compare
a computed statistic (e.g. the difference in means or medians be-
tween two conditions) with the value of that statistic for all other
possible arrangements of the data obtained in that patient. The
P-value is simply the proportion of arrangements leading to a
value of the statistic as large as, or larger than, the value obtained
from the actual data. The key question is how likely is it by chance
that a difference in means was as large as the observed difference
between two conditions, e.g. treatment versus no treatment.
In the design used here (Fig. 1), we can compare the difference
in mean scores between two phases of the trial, e.g. OFF
treatment (Phase A1 and Phase A2) compared with ON drug
(Phase B). Suppose the difference in mean scores ON versus
OFF treatment for the patient who underwent the protocol
shown in Fig. 1A is Z. Randomization tests consider all other pos-
sible rearrangements of the data for this patient, within the con-
straints of the trial design (Fig. 1B). For each of these different
permutations of when the drug might start and duration of treat-
ment, the difference in means for each possible A1, A2 and B
period is computed using the data set from the patient. Then
the probability that other possible rearrangements of the data
result in a value as large as, or larger than, Z is calculated. This
simple permutation principle allows us to ask whether there was a
significant change in performance ON drug by comparing the
actual difference in means ON and OFF treatment, with all the
other potential differences in means. If the drug has a significant
effect during the period it is given, we would expect that the
mean of performance ON the drug compared with periods OFF
would be larger than all the other possible arrangements of the
data set from this patient.
Note that this particular patient only had the drug for the period
shown in Fig. 1A, but the data from the patient are simply
Figure 1 Randomization of treatment allocation and permutation tests. (A) Randomization profile for a single patient. In this case, the
treatment phase with rotigotine (Phase B, denoted in red) started on Day 7, and its duration was randomized to 8 days. Therefore, the
patient participated in six baseline assessments (Phase A1, Sessions 1–6) and six follow-up sessions after discontinuation of rotigotine
(Phase A2, Sessions 15–20). Placebo patch sessions are denoted in orange while sessions without any patches are shown in yellow. The
actual difference in performance between treatment (Phase B) and the OFF treatment phases (A1 and A2) was ranked against the
differences between phases produced by all other possible combinations of treatment allocation, given the limits in phase onset and
duration. (B) All the possible permutations of pretreatment (Phase A1), treatment (Phase B) and post-treatment phase (Phase A2).
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reshuffled to produce potential means for ON and OFF treatment
if the drug period had been as shown for all the other permuta-
tions. If there is no significant effect of drug, we would expect the
actual difference in mean performance ON and OFF drug to be
very similar to the means from all other possible permutations
from this data set. In effect, therefore, each patient acts as their
own control. We calculate what the means would have been for
Phases A1, B and A2, as if the patient had started the drug a day
earlier or a day later or even 2 days later; or if the time on the
drug had been longer or shorter than it actually was within the
constraints of all the permutations possible (Fig. 1B). Then we
compare the differences in means for all these permutations
with the actual, observed difference in means ON and OFF treat-
ment. The P-value gives us the likelihood of obtaining a value as
large as Z by chance, computed from the data set of the patient,
not by comparing mean scores across patients randomized to
receiving treatment or no treatment. Individual P-values are then
combined to obtain a P-value for the entire patient group and
separately for two subgroups with different degrees of prefrontal
lesion involvement by stroke.
Materials and methods
Patients
Individuals older than 18 years with left hemispatial neglect and a
motor deficit due to their first-ever clinically defined right-hemisphere
stroke were prospectively recruited from referrals to the trial team at
The National Hospital for Neurology and Neurosurgery, London. Left
hemispatial neglect was defined as a significant deficit in finding left-
ward targets on standard cancellation or visual search tasks, using
established criteria (Wilson et al., 1987; Gauthier et al., 1989;
Mesulam, 2000). A deficit on the line bisection test alone was not
sufficient for inclusion. Motor deficit was defined as weakness of at
least wrist and finger extension and finger abduction to 44 + on the
Medical Research Council scale. Patients were eligible only if stroke
onset was at least 9 days before the first assessment session.
Exclusion criteria were as follows: a pre-existing neurological condi-
tion (e.g. dementia, Parkinson’s disease, multiple sclerosis) that would
confound cognitive or motor assessments; acute concomitant illness
(e.g. infection, unstable angina, myocardial infarction or heart, respira-
tory, renal or liver failure); systolic blood pressure 5120 mmHg and/or
diastolic 570 mmHg (as dopamine agonists may lead to postural
hypotension, especially during dose escalation); exposure to any
other investigational drug within 30 days of enrolment in the study;
presence of clinically significant drug or alcohol abuse within the pre-
vious 6 months; pregnancy; and breast-feeding.
All patients provided written informed consent before participating
in the trial. The study protocol and all relevant documents and
procedures were approved by the National Research Ethics
Service and the Medicines and Healthcare products Regulatory
Agency.
Lesion analysis
According to our hypothesis, the major target of rotigotine for cogni-
tive effects is likely to be dopamine D1 receptors in prefrontal cortex.
Therefore, to assess whether response to rotigotine depends on the
degree of preservation of the prefrontal cortex, we stratified the
patients into two subgroups according to the extent of the prefrontal
cortical involvement, as quantified by high-resolution MRI. To this
end, we used the lesion mapping technique described in Mort et al.
(2003). Briefly, each patient’s stroke lesion was manually delineated at
every single axial slice of their native T1 MRI as a 3D volume of
interest using MRIcron software (Rorden and Brett, 2000), http://
www.cabiatl.com/mricro/. The volume of interest of each patient’s
lesion was then registered to a standard Montreal Neurological
Institute (MNI) T1 template in SPM8b (http://www.fil.ion.ucl.ac.uk/
spm/), applying cost function masking of the lesioned area to obtain
optimal normalization (Brett et al., 2001). Then, the percentage of
prefrontal involvement was quantified for each patient, by comparing
their normalized brain lesion to a prefrontal template, defined
using the PickAtlas SPM toolbox (http://fmri.wfubmc.edu/software/
PickAtlas).
Study design
We used a double-blind, placebo-controlled ‘ABA’ randomized design
consisting of three consecutive phases: (i) baseline pretreatment phase
(Phase A1); (ii) treatment with rotigotine transdermal patches
(Phase B) and (iii) post-treatment phase (Phase A2).
The duration of each phase was randomized within limits, such that,
in each patient, A1 + B + A2 consisted of a total of 20 assessment
sessions. However, the precise durations of A1, B and A2 varied
across individuals, with both patients and investigators blind to the
precise duration of each of these phases in any given patient. Note
that in this design, all patients receive placebo and drug at different
stages of the trial, with the exact time at which drug is started and the
duration of treatment randomized across individuals.
Phase A1 started on Session 1 and its duration was randomized
(across individuals) to between 5 and 9 days. Observations during
this phase established the baseline performance. Phase B, when
rotigotine was administered, could commence on Day 6 to Day 10,
and its duration was a minimum of seven and a maximum of 11 ses-
sions. Finally, Phase A2, when patients were assessed after the discon-
tinuation of rotigotine, was randomized to begin between Sessions 13
and 17 and it lasted for the remaining four to eight sessions.
For the purpose of placebo control, all patients received a placebo
patch in the period between Sessions 6 and 16, on the days they were
not receiving rotigotine. Placebo and rotigotine patches were visually
identical. All investigators, clinical staff, patients and carers were
masked to treatment assignment.
Each patient was randomly assigned a pattern of onset and duration
of the treatment and baseline phases, within the duration limits
described above. As an example, the randomization profile of one of
the participants is presented in Fig. 1A. In this example, the patient
had six baseline assessments, followed by 8 days on rotigotine
(Sessions 7–14) and six follow-up assessments after discontinuation
of the drug. In Fig. 1A, the yellow shading shows the minimum
number of sessions in Phases A1 and A2, while red shading denotes
the treatment phase (Phase B). Orange depicts any additional sessions
in Phases A1 and A2 when the patient received placebo patches. All
possible permutations of pretreatment, treatment and post-treatment
phases within the constraints of the design are shown in Fig. 1B. In
total, there were 15 possible permutations.
Clinical and behavioural testing
Each patient participated in 20 consecutive assessment sessions. The
first 17 sessions were performed daily. The final three follow-up as-
sessments were conducted at weekly intervals. Each session consisted
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of tests of spatial neglect, spatial working memory, selective and sus-
tained attention and motor performance.
Spatial neglect was evaluated with the line bisection test from the
Behavioural Inattention Test Battery (Wilson et al., 1987) and with
three visual search tasks: Mesulam shape cancellation (Mesulam,
2000) and bells cancellation task (Gauthier et al., 1989), performed
on A3 sheets, and a visual search task performed on a touch screen
(18 inch diagonal), in which no visible markings were left at the loca-
tion of the cancelled targets (Parton et al., 2006). There was a 2-min
time limit for all visual search tasks.
Spatial working memory was measured with a vertical analogue of
the Corsi spatial span test (Malhotra et al., 2005), and also using the
rate of revisiting of previously cancelled targets obtained from the
touch screen visual search task (Mannan et al., 2005; Parton et al.,
2006). Selective attention and sustained attention were assessed using
a visual salience and vigilance task, which has been previously used in
patients with prefrontal lesions (Barcelo et al., 2000). As shown in
Fig. 7A, in this task, participants were asked to detect targets (inverted
triangles) among sequences of distractors (upright triangles) randomly
presented to the ipsilesional and contralesional visual fields and to
respond to targets with a speeded button press. Targets could be of
the same colour as the distractors (low visual salience) or of a different
colour (high visual salience targets). As a measure of selective atten-
tion, we used the ratio of the reaction time to high visual salience
targets over the reaction time to low visual salience targets.
Furthermore, using this task, we quantified sustained attention over
time, by measuring the difference in reaction time and per cent correct
responses between the first and the second half of each experimental
session.
Motor performance was evaluated in all patients using the
Motricity Index (Wade, 1992; Bohannon, 1999) and with grip and
pinch dynamometry (Sunderland et al., 1989). Where the patient’s
level of weakness permitted, motor performance was also assessed
using the nine-hole peg test (Mathiowetz et al., 1985b), box and
blocks test (Mathiowetz et al., 1985a) and timed 10 m walk (Wade,
1992).
Drug and placebo administration
During the treatment phase, a rotigotine 9.0 mg skin patch (equivalent
to 4 mg/24 h transdermal absorption) was applied daily by the inves-
tigator. Patients were instructed to wear it 24 h a day. Since rotigotine
takes up to 24 h to reach steady-state levels, application of the drug
patch started immediately after behavioural testing the day before the
drug would be effective. Thus, a patch (drug/placebo) was applied on
the last session of Phase A1 and immediately after behavioural testing
in Sessions 5–15. Therefore, either placebo or rotigotine was in place
during behavioural testing in Sessions 6–16. In the example shown in
Fig. 1A, the patient had a placebo patch applied immediately after
behavioural testing on Day 5 and an active rotigotine patch was
applied after testing on Day 6; the treatment Phase B commenced
on Day 7.
To prevent nausea, a common adverse effect of dopamine agonists,
patients received domperidone 10 mg orally three times daily from
Sessions 1–16. As domperidone does not penetrate the blood–brain
barrier, it should not interfere with the central response to rotigotine
(Quinn et al., 1981). Blood pressure and pulse were recorded and
patients were asked to report any adverse events at each assessment
session.
Statistical analysis
We used a replicated randomized N-of-1 design (Edgington and
Onghena, 2007), which makes it possible to investigate the effects
of an intervention on small groups of patients, provided sufficient as-
sessments are made. Hence, the intensive testing procedure consisted
of 17 consecutive daily assessments, followed by three weekly ones.
This design methodology, the principle of which was developed by
Fisher (1935), is sometimes also referred to as permutation testing.
Critically, it makes no assumptions about the underlying distribution
of the data (Todman and Dugard, 2001) and has been shown to be
particularly robust for studies with small sample sizes (Guyatt et al.,
1990; Ferron and Onghena, 1996).
The aim of our analysis was to identify whether performance during
the treatment phase (B) was significantly improved when compared
with the pretreatment baseline (Phase A1) and with the post-
treatment follow-up (Phase A2). For each patient and each outcome
measure, we first computed three statistics expressing the difference
between phases: (i) difference of the median observation of Phase B
from the median of Phase A1 (B  A1); (ii) difference between the
medians of Phases B and A2 (B  A2) and (iii) difference between the
median of Phase B and the median of Phases A1 and A2 averaged
(B  Am). Therefore, B  Am is the difference between the median of
the treatment phase (B) and the average of the medians of both OFF
treatment phases.
Then each of these measures was ranked against the values of the
same measure computed for all possible rearrangements of the data.
An example of this approach is presented in Fig. 1B. The higher the
ranking of the actual difference ON and OFF rotigotine among all
possible permutations, the higher the probability that the observed
difference was due to the drug. Based on this ranking, for each out-
come measure, we obtained a P-value for each individual patient. This
P-value is derived from the proportion of arrangements leading to a
difference between phases which is as large as, or larger than, the
difference ON and OFF treatment obtained from the actual data.
A group P-value was obtained for each outcome measure, by com-
bining the individual patients’ P-values, using Edgington’s additive
method (Edgington, 1972). The same method was used to obtain P-
values for each of the prefrontal subgroups. Analyses were performed
using the R statistical software (http://www.r-project.org/). Trial
design and analyses were implemented by an expert statistician (E.K.).
Results
Sixteen patients fulfilling the inclusion criteria were prospectively
enrolled in the trial. Patient demographics are presented in
Table 1, and lesion maps are shown in Fig. 2. Compliance with
the treatment protocol was 100%; none of the patients missed
any dose of rotigotine or placebo. All patients attended 20 assess-
ment sessions as per protocol, apart from Patient 7 who missed
one session (Session 11, ON rotigotine), for reasons unrelated to
the trial. There were no serious adverse events during treatment
with rotigotine. Mild adverse effects included fatigue, mild skin
irritation at the site of the patch, and gastrointestinal disturbance,
including nausea, vomiting and diarrhoea, which are all known
potential side effects of rotigotine (Table 2). Importantly, neither
treatment nor assessments were interrupted due to adverse
events.
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Treatment with rotigotine was associated with significant im-
provement in visual search, as quantified by the Mesulam shape
cancellation task. As shown in Fig. 3, for the entire group of 16
neglect patients, the number of targets found on the left side was
significantly higher while ON rotigotine than in the pre- and post-
treatment phases averaged (P = 0.012) or in the post-treatment
phase alone (P = 0.039). Overall, the difference ON and OFF
treatment in the number of targets found on the left side relative
Figure 2 Lesion overlap maps. Axial MRI slices of stroke lesions in (A) the entire group of all 16 patients, (B) the minimal prefrontal
involvement subgroup (eight patients) and (C) the extensive prefrontal involvement subgroup (eight patients). Colour values represent the
number of patients in whom a given voxel was lesioned; note the scale is different for the entire group (A) compared with the subgroups
(B and C).
Table 1 Patient demographics and Mesulam search task results
Patient
ID



















P1 42 Male Right Ischaemic 728 39.4 13.25 22 26.5 26
P2 62 Male Right Ischaemic 70 14.6 24.75 22.5 25.5 27.5
P3 46 Male Right Ischaemic 1381 32.5 1.5 5 24.5 27
P4 63 Female Right Ischaemic 42 11.8 0.25 0 20.75 23
P5 58 Male Right Ischaemic 327 35 0 0 13.5 13
P6 66 Male Right Ischaemic 202 54.7 1 0 18 19
P7 62 Male Right Haemorrhagic 232 0.2 1.75 2.5 16.75 16
P8 74 Male Right Ischaemic 341 35.3 9.75 10.5 22 19.5
P9 53 Male Left Ischaemic 385 5.6 22 28 27 29
P10 24 Male Right Haemorrhagic 221 7.2 0 0 16.25 8
P11 60 Male Right Haemorrhagic 1990 2.4 10.75 20.5 23.25 25.5
P12 62 Male Right Ischaemic 941 33.5 2 0.5 26 28
P13 72 Female Right Haemorrhagic 1712 32.6 2 8 25.5 22
P14 80 Male Right Ischaemic 30 0 22.75 23 24.25 26
P15 51 Male Right Haemorrhagic 104 52.9 6.5 7 23.25 23
P16 49 Male Right Ischaemic 85 9.1 11.75 13 20.25 18
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to baseline was 12.8% higher in the actual treatment allocation
than the mean difference between phases produced by all possible
combinations of treatment onset and duration (Fig. 1). Although
the number of targets found on the right side was somewhat
decreased ON treatment (Fig. 3), the relative difference ON and
OFF treatment was only 0.7% smaller in the actual treatment
allocation when compared with all possible permutations, and
this was not statistically significant (P = 0.466).
Spatial bias in visual search (ratio of difference in the number of
targets found on either side to total number of targets found on
the Mesulam test) also improved significantly on rotigotine when
compared with the post-treatment phase (P = 0.018) or with both
OFF treatment phases (P = 0.016, Fig. 3). There was 8.1% less
rightward bias relative to baseline in the actual treatment alloca-
tion, in comparison to all possible permutations (Fig. 4B).
Next, we evaluated the effect of rotigotine on performance on
the Mesulam test in two patient subgroups, defined according to
the extent of involvement of the prefrontal cortex in the stroke
lesion: a minimal prefrontal involvement subgroup (0–15% of the
prefrontal cortex affected, Fig. 2B) and an extensive prefrontal
subgroup (33–55% of the prefrontal cortex affected, Fig. 2C).
A significant benefit of treatment with rotigotine was noted in
both subgroups (Fig. 5), but for different study parameters.
The number of targets found on the left was significantly higher
ON rotigotine than OFF treatment in the minimal prefrontal sub-
group (P = 0.036), while this effect did not reach significance in
the extensive prefrontal subgroup (P = 0.084). Conversely, spatial
bias improved significantly ON rotigotine in the extensive pre-
frontal group (P = 0.018), but not in the minimal prefrontal
group (P = 0.177). Therefore, rotigotine was associated with sig-
nificant improvement in the Mesulam shape cancellation task in
the entire patient group and in both prefrontal subgroups, but the
significant measures varied between the two subgroups.
The effect of rotigotine on performance on the Mesulam can-
cellation task was also assessed on a subject-by-subject basis
(Fig. 6 and Table 1). Response to the drug was characterized by
considerable variability, with some subjects showing remarkable
improvement ON the drug when compared with average perform-
ance in the phases OFF rotigotine and others showing smaller
positive effects or even a small decline in the number of targets
found on the left side while ON the drug (Table 1). The results of
Figure 3 Difference in performance on the Mesulam cancellation task ON and OFF rotigotine for all patients. A heatmap of the difference
in targets found ON and OFF treatment for the entire patient group is overlaid on a Mesulam test sheet. Colour represents difference ON
and OFF treatment in the number of targets found per session per patient at each target location. Treatment with rotigotine was
associated with a significant increase in the number of targets identified on the left side. A decrease in the number of targets found during
treatment in a smaller area on the right-hand side was not statistically significant.










Fatigue 4 (25%) P8 (1), P9 (3),
P10 (2),
P14 (1)
1 (6%) P9 (1)
Topical skin
reaction
1 (6%) P6 (3) 0




Vomiting 1 (6%) P3 (1) 0
Diarrhoea 2 (13%) P4 (2), P8 (1) 0
Number of patients who had at least one adverse event, patient codes (corres-
ponding to those in Table 1) and number of occurrences per patient on rotigotine
and on placebo. P = Patient.
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permutation analysis for each patient on the Mesulam task are
illustrated in Fig. 6A and B for difference in the targets found
on the left side (positive values in Fig. 6A indicate improvement)
and alteration in spatial bias (leftward shifts in Fig. 6B denote
improvement). Red circles demonstrate ON versus OFF treatment
values (i.e. the actual treatment allocation data); grey lines show
the range of such values for all possible permutations of the data
in that patient and grey squares indicate the mean difference
derived from all possible permutations of the data. Note that the
ranges for each patient vary depending upon the variability of
performance measures across all permutations (shufflings) of the
data set in each patient.
Some patients showed a strong effect ON drug when compared
with all possible permutations of the data (red circles well to the
right of the range). Conversely, in other patients the differences in
the actual treatment allocation were comparable to differences in
other arrangements of the data, suggesting little effect of rotigo-
tine on performance. Moreover, as shown in Fig. 6C, the effect of
rotigotine did not appear to depend on baseline performance
(degree of neglect), as a beneficial effect—or otherwise—was
observed across a range of baseline performance. Additionally,
the effect of rotigotine did not appear to be affected by age, as
there was no significant difference between age of patients who
responded best to treatment (Patients 1, 3, 9, 11 and 13) and
those who showed poor response [t(14) = 0.61; P = 0.55]. Nor
was there any relationship to adverse effects: at least two patients
who showed benefit in visual search had no adverse effects ON
rotigotine, and overall the adverse effect profile was comparable
between patients who responded to rotigotine and those who did
not (Table 2). Analysis of lesions of patients who showed a
response versus those who did not is provided in the online
Supplementary material, but we would urge caution in interpreting
these data, given the relatively small sample size.
Unlike the results for the Mesulam cancellation task, there were
no significant positive or negative effects of treatment with roti-
gotine on bells cancellation or touch screen visual search tasks at
the group or subgroups level. Similarly, we did not observe any
significant alteration in line bisection performance, although we
note that mean pretreatment baseline performance in line bisec-
tion in our sample was relatively close to normal (mean rightward
deviation: 4.5 mm).
One possible mechanism by which rotigotine might have
exerted its positive effect on visual search in the Mesulam cancel-
lation task could be by enhancing spatial working memory.
We quantified working memory performance using a vertical
analogue of the Corsi blocks task and also by measuring the
number of revisits of previously identified targets in the touch
screen visual search task. There was no evidence from either
measure that treatment was associated with improvement of spa-
tial working memory. Thus, performance on the vertical Corsi task
did not improve on rotigotine (spatial memory span for the entire
group: P = 0.377; minimal prefrontal subgroup: P = 0.548; exten-
sive prefrontal subgroup: P = 0.287), and treatment was not
associated with a significant decrease in the number of revisits
in the touch screen task (entire group: P = 0.821; minimal pre-
frontal subgroup: P = 0.489; extensive prefrontal subgroup:
P = 0.909).
An alternative hypothesis is that the effect of rotigotine on
visual search might be due to an improvement of selective atten-
tion through D1 receptor modulation (Noudoost and Moore,
Figure 4 Overall effect of rotigotine treatment on Mesulam cancellation task. Y-axes represent per cent difference between performance
ON treatment (Phase B) and OFF treatment (average of Phases A1 and A2), relative to OFF treatment baseline. The actual differences ON
and OFF treatment (in red) are compared with the average (average SEM) of differences between Phases B and the average of A1 and
A2 produced by all possible combinations of the data (in grey). *P50.05. (A) The difference ON and OFF treatment in the number of
targets found on the left side relative to baseline was higher in the actual treatment allocation, compared with all other possible per-
mutations. (B) There was significantly less rightward bias in the location of the targets found during treatment with rotigotine, in com-
parison to differences produced by all possible permutations of the data.
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2011). We used a specific task to directly quantify attention (visual
salience and vigilance task). In this task, we measured the ratio of
reaction times to respond to high salience targets versus low sa-
lience targets presented on the left or right of fixation. At the
group level, there was a significant increase in this ratio for left-
sided targets during treatment, in comparison to the pretreatment
baseline (P = 0.03, Fig. 7). This effect was of only marginal sig-
nificance when comparing treatment to the post-treatment base-
line alone (P = 0.068), or to the average of both OFF treatment
phases (P = 0.063).
In the extensive prefrontal subgroup, treatment with rotigotine
was associated with an increase in reaction time ratio to respond
to salient/non-salient targets. This was when compared with the
pretreatment baseline or to the average of both treatment phases,
both for left-sided targets (P = 0.016 and P = 0.039, respectively)
and overall for both left- and right-sided targets (comparison with
pretreatment phase: P = 0.008, and with OFF treatment average:
P = 0.008). Conversely, in the minimal prefrontal subgroup, the
effect of rotigotine on the same measure of selective attention
was not significant (left-sided targets, comparison with OFF treat-
ment average: P = 0.113), even though at baseline reaction times
ratios were not significantly different between the two patient
subgroups (P = 0.537). Therefore, treatment with rotigotine
might be associated with a modulation of selective attention in
neglect, especially in patients with extensive damage in the pre-
frontal cortex.
Figure 5 Difference in Mesulam task performance ON and OFF rotigotine in the two subgroups defined according to involvement of
prefrontal cortex in the stroke lesion. (A) In the subgroup with minimal prefrontal involvement, the number of targets found on the left
side increased significantly on treatment. (B) Patients with extensive prefrontal involvement showed a significant reduction in rightward
spatial bias during treatment.
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A further possibility could be that rotigotine improved visual
search by enhancing non-selective sustained attention, a cognitive
ability that can be impaired in neglect (Hjaltason et al., 1996;
Robertson et al., 1997b). To control for this possibility, we used
as a measure of sustained attention and alertness across time the
difference in performance between the first and the second half of
each session of the visual salience and vigilance task. However,
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Figure 7 (A) Selective and sustained attention task. Participants detected targets (inverted triangles) among sequences of distractors
(upright triangles) randomly presented to the ipsilesional and contralesional visual fields. Targets could be of the same colour as the
distractors (red—low visual salience) or of a different colour (green—high visual salience). Participants were asked to respond with a
button press as soon as they saw a target of any type. (B) Effect of rotigotine treatment on selective attention for left-sided targets. Y-axes
represent per cent difference between performance ON (Phase B) and pretreatment (Phase A1), relative to pretreatment baseline. The
actual differences ON and pretreatment (in red) are compared with the average (average SEM) of difference between Phases B and A1
produced by all possible combinations of the data (in grey). The difference ON and pretreatment in the ratio of the reaction time (RT) to
salient targets over non-salient targets on the left side relative to baseline was higher in the actual treatment allocation, when compared
with all possible permutations. *P = 0.03. ISI = inter-stimulus interval.
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Figure 6 Mesulam task performance ON and OFF rotigotine in individual patients. Response to rotigotine was variable, across patients
(presented in the same order as in Table 1). (A) Difference in left targets found ON versus OFF treatment. Red circles represent the actual
difference in performance ON and OFF rotigotine for each individual. Grey squares denote the mean difference derived from all possible
permutations of the data while the error bars show the range of values of such means for all possible permutations. Red circles situated on
the right of error bars signify a greater number of targets found while ON the drug when compared with all possible allocations of
treatment and placebo. (B) Difference in spatial bias ON versus OFF treatment. Here leftward shifts in search are displayed in the left. Red
circles on the left of error bars signify less rightward bias in the location of the targets found while on the drug when compared with all
possible allocations of treatment and placebo. (C) Difference in number of targets found on left as a function of number of targets found
OFF treatment. Improvements occurred both in patients with poor performance at baseline (small number of targets found on the left
side) and in those with good baseline performance.
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either the entire group (P = 0.697) or the two patient subgroups
(minimal prefrontal: P = 0.555 and extensive prefrontal:
P = 0.727).
Finally, treatment with rotigotine was not associated with any
significant improvement or worsening in any of the motor tasks in
the patient group as a whole, or in either of the patient sub-
groups. Thus, in this sample, there was no evidence of a positive
effect on motor control after stroke using rotigotine.
Discussion
We performed a randomized, double-blind, placebo-controlled
study of the dopamine agonist rotigotine in patients with hemi-
spatial neglect and left-sided motor weakness following right-
hemisphere stroke. A randomized ABA design was used, with
each patient assessed in three phases: before, during and after
treatment with rotigotine, for a total of 20 consecutive sessions.
The exact number of sessions within each phase was randomized
and the difference ON and OFF rotigotine in the actual treatment
allocation was compared with the differences derived from all
possible permutations of phase durations computed from each
patient’s data. This rigorous methodology enabled us to assess
the effectiveness of rotigotine without the need for an extensive
sample size (Ferron and Onghena, 1996; Edgington and Onghena,
2007). Nevertheless, our relatively small sample of 16 patients is
still the largest that has been reported to date in any study on
drug treatment in neglect following stroke (Fleet et al., 1987;
Geminiani et al., 1998; Grujic et al., 1998; Hurford et al., 1998;
Barrett et al., 1999; Mukand et al., 2001; Malhotra et al., 2006;
Buxbaum et al., 2007; Vossel et al., 2010).
Treatment with rotigotine was associated with a significant in-
crease in number of targets identified on the left and a decrease in
the pathological rightward spatial bias on the Mesulam shape can-
cellation task, a visual search test widely used to assess neglect in
clinical practice. Of note, rotigotine was associated with a 12.8%
increase in number of targets found on the left in the actual treat-
ment allocation in comparison to all possible permutations of the
data. However, there was considerable variation across individuals
and it is, as yet, unclear which patients are most likely to benefit.
Importantly, response did not appear to depend upon baseline
degree of neglect or extent of prefrontal involvement.
Although the positive effect of rotigotine was moderate, it is
potentially important, bearing in mind, that our study design
investigated short-term treatment over only 7–11 days. The
result compares favourably with the effects of most other neuro-
modulatory agents established in the clinical treatment of cognitive
deficits, which overall are typically very modest (Husain and
Mehta, 2011), e.g. of the order of 3% over several months for
cholinesterase inhibitors used for the treatment of dementia
(Erkinjuntti et al., 2002). Of course, the clinical use of such treat-
ments has been challenged on the basis of their small overall
effect sizes, but it is also apparent that there is considerable het-
erogeneity of response, with some patients demonstrating very
strong effects while others show none.
Although the relatively small sample size of our own study does
not allow for a systematic data-driven investigation of the possible
determinants of between-subject variability, larger studies in the
future might identify possible predictors of treatment response,
which could permit patient selection for targeted treatment. For
example, our study included patients with a wide range of time
since stroke and did not differentiate between patients with an
ischaemic or haemorrhagic aetiology. Future investigations with
larger samples might attempt to control for such variables. In
addition, it would be crucial to examine the impact of the drug
on everyday life, using functional outcome measures: activities
of daily living and functional measures of neglect (Azouvi
et al., 2003).
It should be noted that we did not identify any significant effects
of rotigotine on two other visual search tasks (bells cancellation and
touch screen cancellation tests). Possible reasons for this discrep-
ancy might relate to display parameters in these tasks. Specifically,
in the bells cancellation task there is a smaller number of targets
and distractors than in the Mesulam test (34 versus 60 targets; 278
versus 311 distractors), and in the touch screen visual search task
the targets and distractors were presented in a smaller area. These
parameters may render the bells and touch screen visual search
tests less sensitive than the Mesulam shape cancellation task
(Kaplan et al., 1991), making the effects of treatment less discern-
ible. Rightward deviation in line bisection also did not improve
significantly on treatment. Given that performance in the pre-
treatment baseline phase was already close to normal in our patient
group, this may represent a ceiling effect. Response to treatment
did not appear to depend simply on task difficulty or complexity, as
rotigotine had a significant improvement on the Mesulam task,
while there was no significant effect of the drug in arguably both
simpler (line bisection, Bells cancellation) and more complex tasks
(touch screen cancellation).
The current study was designed not only to assess the effect-
iveness of rotigotine in ameliorating spatial bias in neglect but also
to identify possible cognitive mechanisms that may mediate this
effect. Based on existing evidence on the role of D1 dopamine
receptor activity in spatial working memory (Funahashi and
Kubota, 1994; Castner et al., 2000; Castner and Goldman-Rakic,
2004), we hypothesized that rotigotine might improve perform-
ance on cancellation tasks by enhancing working memory for the
location of previously cancelled targets, and therefore diminishing
‘revisiting’ of previously explored locations (Mannan et al., 2005;
Parton et al., 2006). However, rotigotine was not associated with
improvement of spatial working memory, indexed either indirectly,
by measuring the number of revisits in the touch screen cancella-
tion task (Parton et al., 2006), or directly, using a vertical variant
of the Corsi spatial memory task (Malhotra et al., 2005).
An alternative mechanism that may explain the positive effects
of rotigotine in the Mesulam cancellation task would consist of a
direct enhancement of selective attention by increased dopamin-
ergic activity. This hypothesis is compatible with recent evidence
that local administration of a D1 dopamine receptor modulator in
the monkey frontal eye field alters selectivity and reliability of eye
movements to visual targets and modulates neuronal activity in
visual area V4 in the same way that selective voluntary attention
does (Noudoost and Moore, 2011). If this were the case also in
humans with visual neglect, one might expect the drug to induce
more effective allocation of voluntary attention to task-relevant
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target stimuli and, correspondingly, less involuntary attentional
capture by the task-irrelevant (but visually salient) distractors,
therefore making identification of correct items more effective.
Interestingly, the results from our combined visual salience and
vigilance task suggest that ON rotigotine responses to less salient
(but equally task-relevant) targets became faster on the left, rela-
tive to more salient ones. This might be in keeping with more
effective voluntary allocation of selective attention to task-relevant
visual targets and less involuntary attentional capture, driven by
stimulus salience, on rotigotine. Therefore, it is possible that
rotigotine improved performance on the Mesulam search task
by enhancing selective attention to targets, while reducing invol-
untary attentional capture by distractors. This result is consistent
with the known role of dopamine in mediating attention switching
and arousal to behaviourally relevant stimuli and modulating
goal-directed behaviour (Bromberg-Martin et al., 2010;
Cools, 2011).
Note that if the positive effects of rotigotine on neglect were
due simply to non-specific, motivational processes, one would
expect a general improvement across multiple tasks. Instead, we
observed specific effects on the Mesulam search task and on our
selective and sustained attention task. The results from the latter
paradigm are particularly useful as they show that rotigotine had a
specific effect in improving selective attention to task-relevant tar-
gets, over detection of salient, but task-irrelevant targets. Non-
selective, sustained attention can be impaired in neglect and has
been shown to correlate with neglect severity (Hjaltason et al.,
1996; Robertson et al., 1997b). Importantly, we did not find
any effect on sustained attention on this task, which would be
expected if the effects of rotigotine were to improve non-specific
arousal and motivation. Thus, the effects of treatment seem to be
highly specific, improving selective, voluntary attention rather than
enhancing sustained, non-selective attention across time.
We have hypothesized that modulation of D1 receptor activity
might provide a possible mechanism by which visual search in
neglect can be ameliorated through enhancement of working
memory or selective attention. In comparison to other dopamine
agonists approved for clinical use, rotigotine has a relatively high
D1 receptor affinity. However, it should be noted that it has an
even higher affinity to D2 and D3 receptors (Belluzzi et al., 1994;
Jenner, 2005; Naidu and Chaudhuri, 2007). Therefore, the effect
of rotigotine on visual search in the patients we studied might also
have been mediated, at least in part, by D2 and/or D3 agonist
activity.
According to our original hypothesis, the effects of rotigotine in
neglect would be mediated by increased dopaminergic activity in
the right prefrontal cortex. In that case, we would expect to find
benefit from treatment only in patients with relative preservation
of right prefrontal cortex. However, we demonstrated that
rotigotine was associated with significant improvement on the
Mesulam shape cancellation task in both the minimal and the
extensive prefrontal involvement subgroup. This suggests that in-
tegrity of the right prefrontal cortex is not critical in determining
response to rotigotine, at least in the sample of patients we have
assessed in this study. An alternative hypothesis could be that
rotigotine modulates the activity in intact frontoparietal or
fronto-occipital networks (Bartolomeo et al., 2007; Doricchi
et al., 2008; Urbanski et al., 2008; Vuilleumier et al., 2008),
either in the lesioned or in the contralesional hemisphere, effect-
ively ‘rebalancing’ pathological overactivity in structurally intact
brain networks that may contribute to lateralized attentional im-
balance in neglect (Corbetta et al., 2005).
In a prospective study, L-DOPA as an adjuvant of physiotherapy
has been demonstrated to improve motor function in stroke pa-
tients with unilateral weakness (Scheidtmann et al., 2001). We did
not find any significant effect of rotigotine treatment on motor
performance. However, the current study was not designed to
assess drug effects prospectively, and the amount of physiother-
apy received by each patient was not controlled, therefore
although we did not find an effect of rotigotine alone on motor
performance, it remains an open question whether this drug may
benefit motor rehabilitation when used as adjuvant of physiother-
apy. Indeed, given the well-recognized role of dopamine in com-
plex reinforcement learning (Dayan and Balleine, 2002; Wise,
2004), a possible synergistic role of dopamine agonists in novel
rehabilitative approaches that aim to improve spatial awareness in
neglect (Parton et al., 2004) also presents itself as an important
question for future research.
This study was the first successful randomized, double-blind pla-
cebo controlled study of the dopamine agonist rotigotine in a
group of stroke patients with hemispatial neglect and unilateral
weakness. Rotigotine was reasonably well tolerated in this setting
and was associated with significant improvement in one visual
search task. Placebo-controlled N-of-1 randomized design, such
as the one used here, provides a useful means to test proof-of-
principle for potential new therapies. However, larger trials, includ-
ing measures of functional efficacy, will be needed to confirm
whether this treatment may be practical for widespread clinical
use in hemispatial neglect following stroke.
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